Amgen vs Tata Motors: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Amgen and Tata Motors side by side

1. 1945Tata Motors

   TELCO is founded

   Tata Engineering and Locomotive Company is established, forming the roots of Tata Motors.

2. 1954Tata Motors

   Commercial vehicle production begins

   Tata enters commercial-vehicle production through a collaboration with Daimler-Benz.

3. 1954Tata Motors

   First Indian-Built Commercial Vehicle

   TELCO produces its first commercial vehicle in collaboration with Daimler-Benz, marking India's entry into domestic truck manufacturing.

4. 1980Amgen

   Applied Molecular Genetics is incorporated

   Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.

5. 1983Amgen

   Nasdaq listing and the erythropoietin clone

   Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.

6. 1984Amgen

   Kirin-Amgen joint venture formed

   Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.

7. 1985Amgen

   G-CSF cloned, leading to Neupogen

   While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.

8. 1989Amgen

   FDA approves Epogen

   The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.

9. 1991Amgen

   Neupogen approved, giving Amgen a second franchise

   The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.

10. 1991Amgen

    Amgen wins the erythropoietin patent fight

    On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.

11. 1998Tata Motors

    Tata Indica Launches

    Tata Motors launches the Indica, its first indigenously designed passenger car, marking a major expansion beyond commercial vehicles.

12. 2001Amgen

    FDA approves Aranesp, the longer-acting EPO

    Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.

13. 2002Amgen

    US$16 billion Immunex acquisition brings Enbrel in-house

    Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.

14. 2004Tata Motors

    Daewoo commercial vehicle business acquired

    Tata Motors acquires Daewoo Commercial Vehicle in South Korea, expanding heavy-truck capabilities.

15. 2008Tata Motors

    Jaguar Land Rover acquired

    Tata Motors acquires Jaguar Land Rover from Ford, transforming old Tata Motors into a global automaker.

16. 2010Amgen

    Prolia and XGEVA create the bone health franchise

    The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.

17. 2019Amgen

    US$13.4 billion purchase of Otezla from Celgene

    Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.

18. 2020Amgen

    Amgen joins the Dow Jones Industrial Average

    Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.

19. 2023Amgen

    US$27.8 billion Horizon Therapeutics acquisition closes

    Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.

20. 2023Tata Motors

    Sanand plant acquisition completed

    Tata Passenger Electric Mobility completes the acquisition of Ford India's Sanand plant.

21. 2024Amgen

    Imdelltra becomes the first T-cell engager for small cell lung cancer

    The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.

22. 2024Tata Motors

    Ratan Tata Dies

    Ratan Tata, the Tata Group chairman who led the transformative Jaguar Land Rover acquisition, dies in October 2024.

23. 2025Amgen

    VESALIUS-CV extends the Repatha case to primary prevention

    In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.

24. 2025Tata Motors

    Demerger takes effect

    The composite scheme separates commercial vehicles from passenger vehicles and JLR, changing the current Tata Motors Ltd perimeter.

25. 2026Amgen

    Medicare price setting reaches Enbrel and Otezla

    Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.

26. 2026Tata Motors

    FY2026 revenue is reported

    Current Tata Motors Limited reports FY2026 consolidated revenue of ~$9.73B (INR83,855 Cr).

27. 2026Tata Motors

    Iveco tender offer launched

    After Consob approval, Tata Motors launches a EUR14.10-per-share all-cash offer for Iveco Group, open September 7 to October 26, 2026.

Acquisitions

Questions about Amgen vs Tata Motors